←
Dan Landau2,222 posts
Dan Landau avatar

Dan Landau

@landau_lab

Somatic evolution, cancer genomics (Weill Cornell/NYGC) // Chair, department of Systems and Computational Biology (WCM) // Oncologist (NYP)

◷ Joined August 2015▧ 342 Photos and videos
Dan Landau avatar
Dan Landau@landau_lab·Sep 1

The rumors are true! I am beyond excited to take on this new adventure as the inaugural chair of the Systems and Computational Biology (SCB) Department at @WeillCornell thread 👇

Congratulations to our @WCMEnglanderIPM colleague Dr. Dan Landau (@landau_lab) on being named Inaugural Chair of the Department of Systems and Computational Biomedicine @WeillCornell! #ArtificialIntelligence #LiquidBiopsy #genomics #biomedicine #DreamBig news.weill.cornell.edu/news/…

Post attachment
Josh Schiffman avatar
⟳ Dan Landau retweeted
Josh Schiffman@jsschiffman·5h

Train the same AI 3 times. Same behavior, different circuits. So is a circuit the algorithm—or just one implementation of it? Meet ACE: a new way to understand AI. It extracts what different wirings share—to explain why AIs grok and to steer LLMs up to 32B 🧵 #NeurIPS2026

0:15
Sasha Gusev avatar
⟳ Dan Landau retweeted
Sasha Gusev@SashaGusevPosts·Nov 16

Exciting new work led by Sarah Urbut (@tigerstatdoc) in the growing longitudinal EHR methods family -- now unifying polygenic and monogenic paradigms.

Post attachment

Our preprint led by @tigerstatdoc & @SashaGusevPosts enabling refined risk stratification for those with strong monogenic or polygenic predispositions modeling age-dependent effects & longitudinal EHRs medrxiv.org/content/10.64898… @medrxivpreprint

Faisal Mahmood avatar
⟳ Dan Landau retweeted
Faisal Mahmood@AI4Pathology·Nov 17

So excited to announce Aevius Labs @aeviuslabs, the third startup to spin out of our research lab! The company builds on our research to make medicine computable. Especially proud to see two of our superstar former trainees, @RowlandPettit (CEO) and @MYLu97 (CTO), leading the company. businesswire.com/news/home/2…

Jarvis avatar
⟳ Dan Landau retweeted
Jarvis@jarvis_best·Nov 16

THE STOCK MARKET IS LITERALLY GOING TO ZERO JUST HIRE THE MAN BACK GAAAAAAAAAAAAAAAAA

Kalshi@KalshiNov 16

BREAKING: Nvidia’s board says it is not looking at returning Jensen Huang to the CEO role Jensen's odds plument to 6%.

Post attachmentPost attachment
Caleb Lareau avatar
⟳ Dan Landau retweeted
Caleb Lareau@CalebLareau·Nov 16

The code of life is written in nucleic acids, but proteins carry out the instructions. New work from @MSKCancerCenter led by the brilliant @LauraCKida introduces sctRNA-seq, a new single-cell assay that defines how cells translate between these languages biorxiv.org/content/10.64898…

Joe Pickrell avatar
⟳ Dan Landau retweeted
Joe Pickrell@joe_pickrell·Nov 16

"Is the Bitter Lesson coming to genomic prediction? An untuned tabular foundation model matches or beats specialized methods" [so: yes] biorxiv.org/content/10.64898…

Vijay Sankaran avatar
⟳ Dan Landau retweeted
Vijay Sankaran@bloodgenes·Nov 10

WOW!! Incredibly exciting to see this wonderful news! 18 years after we showed that BCL11A was an ideal target for HbF induction, Casgevy received FDA approval, other approaches like post-transcriptional silencing of BCL11A have shown clinical success, and now we have these results from @BeamTx! 👏👏

Post attachment

1/🚨WOW! Beam Therapeutics has announced positive topline results from its BEACON Phase 1/2 study aimed to evaluate ristoglogene autogetemcel (risto-cel) - formally known as $BEAM - 101, in sickle cell disease patients (SCD) with severe vaso-occlusive crises (VOCs). Not only did Beam’s BEACON trial successfully achieved its primary efficacy endpoint - freedom from severe Vaso-occlusive Crises (VOCs) for at least 12 consecutive months, the trail also met all of its primary safety endpoints and secondary endpoints - including freedom from inpatient hospitalization for severe VOCs during a period of 12 consecutive months. These outstanding results supports Beam’s planned U.S. Biologics License Application (BLA) submission to the U.S FDA for risto-cel, which is expected as early as Year-End 2026 - making it Beam’s first potential commercial product in the market.

Post attachment
Dan Landau avatar
Dan Landau@landau_lab·Nov 10

"I forgot Hemingway's first name. Now I go around saying Ernest Hemingway, Stevie Wonder. Ernest Hemingway, Stevie Wonder." Ellen Bass

Post attachment
Gilad Evrony avatar
⟳ Dan Landau retweeted
Gilad Evrony@giladevrony·Nov 9

Reminder: Abstracts are due tomorrow (Nov 10) for the upcoming Keystone Symposium on 'Somatic Mosaicism'. We have an exciting line-up of speakers, and we will be selecting more from the abstracts! @nlbigas @GenomeDoctor keystonesymposia.org/confere…

Rahul Satija avatar
⟳ Dan Landau retweeted
Rahul Satija@satijalab·Nov 9

Excited to share Seurat v6 and scSLIDE! Single-cell studies usually compare cells, but scSLIDE lets us compare *samples*. Instead of forcing patients into case/control groups, we can model sample-level variation. Paper: cell.com/cell/abstract/S0092… Software: satijalab.org/seurat